# Noveome Biotherapeutics, Inc.

> Noveome Biotherapeutics is a Pittsburgh clinical-stage biopharmaceutical company built around ST266, a multi-targeted secretome of hundreds of biologically active proteins harvested from a novel population of amnion-derived cells. Rather than transplanting cells, Noveome delivers the healing signals those cells secrete - aiming to modulate inflammation, protect nerves, and accelerate tissue repair. Its lead program treats necrotizing enterocolitis, a devastating gut disease in premature infants, with additional pipeline work spanning ophthalmology, neurology, and dermatology.

- **Founded:** 2000
- **Headquarters:** Pittsburgh, Pennsylvania, United States
- **Founders:** William J. Golden (Founder / former Chairman & CEO), George L. Sing (Co-founder / investor)
- **Team size:** ~30 employees
- **Products:** ST266, ST266 for Necrotizing Enterocolitis (NEC), ST266 ophthalmology / neurology / dermatology programs
- **Notable:** Developed ST266, a multi-targeted secretome with hundreds of biologically active proteins from amnion-derived cells, Received FDA notification to proceed with its Phase 1-2 NEC clinical trial (December 2023), Completed treatment of the first premature infant in the NEC trial (November 2024)

## Products & services

- **ST266** — A first-of-its-kind, multi-targeted secretome containing hundreds of biologically active proteins and factors secreted by a novel population of amnion-derived cells. Designed for neuroprotection, modulation of inflammation, and cell recovery and healing, with multiple delivery routes including topical, intranasal, and parenteral.
- **ST266 for Necrotizing Enterocolitis (NEC)** — Lead clinical program: a Phase 1-2 trial evaluating ST266 plus standard of care in premature infants with NEC, a severe and often fatal intestinal disease. First infant treated November 2024; enrollment expanding across cohorts.
- **ST266 ophthalmology / neurology / dermatology programs** — Earlier-stage pipeline work applying the secretome platform to ocular indications, neurodegenerative and neurological injury (including traumatic brain injury), and wound healing / dermatology.

## Achievements

- Developed ST266, a multi-targeted secretome with hundreds of biologically active proteins from amnion-derived cells
- Received FDA notification to proceed with its Phase 1-2 NEC clinical trial (December 2023)
- Completed treatment of the first premature infant in the NEC trial (November 2024)
- Completed $51M Series E financing (April 2025) to advance the NEC program
- Independent Data Safety Monitoring Board recommended the NEC trial continue without modifications (March 2026)
- Secured a $4M grant from the Commonwealth of Pennsylvania (2020)
- Board includes MIT's Robert S. Langer, Sc.D.

## Latest updates

- **2026-03** — Data Safety Monitoring Board reviewed Cohort 1 safety data and recommended the NEC trial continue without modifications; sites prompted to enroll Cohorts 2 and 3.
- **2025-04** — Completed $51 million Series E financing to support NEC clinical trials.
- **2024-11** — Completed treatment of the first baby in the Phase 1-2 clinical trial evaluating ST266 in NEC.
- **2023-12** — Received FDA notification to proceed with the Phase 1-2 NEC clinical trial.
- **2023-08** — Completed first close of $40 million toward the Series E financing.

## Links

- Website: https://noveome.com
- LinkedIn: https://www.linkedin.com/company/noveome-biotherapeutics-inc.
- Twitter/X: https://twitter.com/NoveomePgh
- Instagram: https://www.instagram.com/noveomebio/
- Facebook: https://www.facebook.com/noveome/

---

Profile page: https://yespress.io/noveome-biotherapeutics-inc
Published by YesPress — https://yespress.io
Last updated: 2026-06-13